XML 39 R27.htm IDEA: XBRL DOCUMENT v3.23.4
REVENUE RECOGNITION (Tables)
 9 Months Ended
Sep. 30, 2023
Revenue Recognition  
SCHEDULE OF DISAGGREGATED REVENUE

 

   2023   2022   2023   2022 
   Three months ended September 30,   Nine months ended September 30, 
   2023   2022   2023   2022 
Product revenues                    
Pharmaceutical product resale income  $394,849   $707,807   $1,237,731   $3,949,771 
Total product revenues  $394,849   $707,807   $1,237,731   $3,949,771 
                     
Service revenues                    
Transaction fee income  $1,617,129   $1,319,483   $4,531,731   $3,947,621 
Data service fee income   46,050    17,950    132,025    54,050 
SaaS fee income   -    10,563    18,299    42,363 
Total service revenues  $1,663,179   $1,347,996   $4,682,055   $4,044,034 
Total revenues  $2,058,028   $2,055,803   $5,919,786   $7,993,805